Compare ZETA & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZETA | LGND |
|---|---|---|
| Founded | 2007 | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 3.9B |
| IPO Year | 2021 | 1992 |
| Metric | ZETA | LGND |
|---|---|---|
| Price | $17.86 | $192.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | $26.25 | ★ $144.71 |
| AVG Volume (30 Days) | ★ 5.3M | 139.7K |
| Earning Date | 11-04-2025 | 08-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,224,703,000.00 | $181,488,000.00 |
| Revenue This Year | $30.55 | $18.41 |
| Revenue Next Year | $30.24 | $18.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 35.87 | ★ 53.40 |
| 52 Week Low | $10.69 | $81.74 |
| 52 Week High | $26.60 | $129.90 |
| Indicator | ZETA | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 44.94 | 50.31 |
| Support Level | $18.88 | $179.65 |
| Resistance Level | $19.96 | $192.44 |
| Average True Range (ATR) | 0.78 | 6.31 |
| MACD | 0.06 | -1.33 |
| Stochastic Oscillator | 19.84 | 44.62 |
Zeta Global Holdings Corp is an omnichannel data-driven cloud platform that provides enterprises with consumer intelligence and marketing automation software. It serves enterprise customers across multiple industries, including financial services, insurance, telecommunications, automotive, travel and hospitality, and retail. Its Zeta Marketing Platform, or ZMP, is an omnichannel marketing platform with identity data at its core. The ZMP can analyze billions of structured and unstructured data points to predict consumer intent by leveraging sophisticated machine learning algorithms and the industry's opted-in data set for omnichannel marketing.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.